https://www.nasdaq.com/press-release/aslan-pharmaceuticals-and-iqvia-biotech-enter-into-strategic-collaboration-2021-12-06
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-announces-participation-at-two-upcoming-virtual-investor
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-to-participate-in-fireside-chat-at-the-12th-annual-jefferies
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-reports-third-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-announces-scientific-collaboration-with-dr-emma-guttman-yassky
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-announces-kol-event-series-to-discuss-atopic-dermatitis
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-announces-expansion-of-scientific-advisory-board-with
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-announces-positive-data-conclusively-establishing-proof-of
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-to-participate-in-the-2021-cantor-virtual-global-healthcare
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-establishes-scientific-advisory-board-chaired-by-distinguished
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-to-present-at-h.c.-wainwright-23rd-annual-global-investment
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-reports-second-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-to-participate-in-fireside-chat-at-btig-virtual-biotechnology-0
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-announces-loan-facility-providing-up-to-%2445-million-from-k2
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-to-participate-in-fireside-chat-at-jefferies-virtual-healthcare
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-reports-first-quarter-2021-financial-results-and-provides
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-to-present-data-on-aslan004-at-society-for-investigative
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-reports-fourth-quarter-and-full-year-2020-financial-results-and
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-appoints-dr-kathleen-metters-as-independent-director-2021-03-18
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-announces-pricing-of-public-offering-of-american-depositary
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-announces-proposed-public-offering-of-american-depositary-0
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-announces-positive-interim-data-from-the-multiple-ascending
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-announces-%2418-million-private-placement-2021-02-25
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-appoints-dr-neil-graham-as-independent-director-2021-02-18
https://www.nasdaq.com/press-release/new-research-published-in-toxicology-in-vitro-provides-insight-into-the
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-opens-expansion-cohort-in-aslan004-atopic-dermatitis-clinical
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-to-present-at-upcoming-piper-sandler-investor-conference-2020
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-reports-third-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-initiates-third-dose-cohort-of-aslan004-in-atopic-dermatitis
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-to-develop-aslan003-as-next-generation-dhodh-inhibitor-in
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-completes-enrolment-in-second-cohort-and-opens-new-sites-in-us
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-to-present-at-h.c.-wainwright-22nd-annual-global-investment
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-resumes-recruitment-of-new-patients-into-aslan004-study-2020-08
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-to-participate-in-fireside-chat-at-btig-virtual-biotechnology
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-appoints-kenneth-kobayashi-md-as-chief-medical-officer-2020-08
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-announces-the-move-of-its-primary-listing-to-nasdaq-and
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-reports-second-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-reports-first-quarter-2020-financial-results-and-provides
https://www.nasdaq.com/press-release/update-aslan-pharmaceuticals-temporarily-pauses-recruitment-of-new-patients-into
https://www.nasdaq.com/press-release/aslan-intends-to-resume-screening-as-soon-as-government-restrictions-are-lifted-and
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-reports-fourth-quarter-and-full-year-2019-financial-results-and
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-to-present-at-9th-annual-svb-leerink-global-healthcare
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-announces-closing-of-us%2415-million-public-offering-of-american
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-announces-pricing-of-%2412.8-million-public-offering-of-american
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-announces-proposed-public-offering-of-american-depositary
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-reports-positive-preliminary-data-from-proof-of-concept-study
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-announces-publication-of-preclinical-data-on-aslan003-in-aml-in
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-announces-topline-results-from-treetopp-global-pivotal-study-of
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-reports-third-quarter-2019-financial-results-and-provides
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-enrolls-first-patient-in-proof-of-concept-study-for-aslan004
https://www.nasdaq.com/press-release/aslan-pharmaceuticals-announces-closing-of-us%243-million-loan-facility-2019-10-18
https://www.nasdaq.com/press-release/new-data-presented-on-aslans-varlitinib-at-esmo-2019-2019-10-02
